Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1538289

registered interest
date	01/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people are prescribed cannabis-based medicines via private healthcare services in the UK.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	76000
answer	answer is ministerial correction date of answer 08/11/2022 answer text <p>The information requested is not held centrally.</p> answering member constituency Colchester answering member printed Will Quince question first answered 08/11/2022 17:16:44 answering member 4423 label Biography information for Will Quince
tabling member	4465 label Biography information for Ronnie Cowan

1247151

registered interest
date	30/10/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department (a) is taking to improve access to medicinal cannabis for people living with multiple sclerosis and (b) if he will publish a Government strategy for improving access to medicinal cannabis.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	109474
answer	answer is ministerial correction date of answer 17/11/2020 answer text <p>Two prescription medicines - Sativex – for the treatment of spasticity in Multiple Sclerosis patients, and Epidyolex – for the treatment of seizures associated with two rare forms of epilepsy, have been made available for prescribing on the National Health Service, where clinically appropriate. This follows clear demonstrated evidence of their safety, and clinical and cost effectiveness.</p><p>We continue to work hard with the health system, industry and researchers to improve the evidence base for other cannabis-based medicines, and to implement the recommendations of NHS England and NHS Improvement’s review on barriers to accessing unlicensed cannabis based medicinal products. This includes the design of clinical trials and the establishment of a national patient registry.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 17/11/2020 13:43:29 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan

1247153

registered interest
date	30/10/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many prescriptions for unlicensed cannabis-based medicines the NHS issued in 2020.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	109476
answer	answer is ministerial correction date of answer 17/11/2020 answer text <p>There have been 1,700 items for Sativex prescribed on an NHS prescription, dispensed in the community in England and submitted to the NHS Business Services Authority for reimbursement for the period November 2019 to August 2020, the latest data available. The following table shows the number of items by month.</p><table><tbody><tr><td><p>Month</p></td><td><p>Items</p></td></tr><tr><td><p>November 2019</p></td><td><p>172</p></td></tr><tr><td><p>December 2019</p></td><td><p>177</p></td></tr><tr><td><p>January 2020</p></td><td><p>175</p></td></tr><tr><td><p>February 2020</p></td><td><p>160</p></td></tr><tr><td><p>March 2020</p></td><td><p>177</p></td></tr><tr><td><p>April 2020</p></td><td><p>187</p></td></tr><tr><td><p>May 2020</p></td><td><p>154</p></td></tr><tr><td><p>June 2020</p></td><td><p>167</p></td></tr><tr><td><p>July 2020</p></td><td><p>178</p></td></tr><tr><td><p>August 2020</p></td><td><p>153</p></td></tr></tbody></table><p><br>The NHS Business Service Authority is unable to provide the number of National Health Service prescription items for unlicensed cannabis-based products dispensed in the community in England. This information is being withheld in accordance with the General Data Protection Regulation, due to the number of items attributed to less than five patients and potential for patient identifiable information to be published.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 109475 question first answered 17/11/2020 14:04:54 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan

1229118

registered interest
date	28/08/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 June 2020 to Question 57346 on Cannabis: Medical Treatments, what progress the Government has made on implementing a patient registry to monitor outcomes among medical cannabis patients.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	82094
answer	answer is ministerial correction date of answer 14/09/2020 answer text <p>The patient registry for cannabis-based products for medicinal use is currently being developed by NHS England and NHS Improvement with input from specialist clinicians and other advisory bodies. The purpose of this registry is to collect a uniform data set for patients prescribed these products, including patient outcomes. NHS England and NHS Improvement intends to pilot the registry this autumn, to enable operational use as soon as practicable.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 14/09/2020 18:28:31 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan

1229119

registered interest
date	28/08/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many unlicensed cannabis-based products have been prescribed on an NHS prescription, dispensed in the community in England and submitted to the NHS Business Services Authority for reimbursement in each month from November 2018 to August 2020.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	82095
answer	answer is ministerial correction date of answer 14/09/2020 answer text <p>The NHS Business Services Authority is unable to provide the number of National Health Service prescription items for unlicensed cannabis-based products dispensed in community pharmacy in England. This information is being withheld in accordance with the General Data Protection Regulation, due to the number of items attributed to less than five patients and potential for patient identifiable information to be published.</p><p>313 private prescription items for unlicensed cannabis-based products were prescribed and dispensed in community pharmacy in England (November 2018 – February 2020). During the COVID-19 outbreak, the NHS Business Services Authority temporarily suspended the processing of private prescriptions of this nature, so data between March 2020 and August 2020 is currently unavailable.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 82096 question first answered 14/09/2020 19:12:55 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan

1229120

registered interest
date	28/08/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many private prescription items for unlicensed cannabis-based medicines have been prescribed and submitted to the NHS Business Services Authority in each month from November 2018 to August 2020.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	82096
answer	answer is ministerial correction date of answer 14/09/2020 answer text <p>The NHS Business Services Authority is unable to provide the number of National Health Service prescription items for unlicensed cannabis-based products dispensed in community pharmacy in England. This information is being withheld in accordance with the General Data Protection Regulation, due to the number of items attributed to less than five patients and potential for patient identifiable information to be published.</p><p>313 private prescription items for unlicensed cannabis-based products were prescribed and dispensed in community pharmacy in England (November 2018 – February 2020). During the COVID-19 outbreak, the NHS Business Services Authority temporarily suspended the processing of private prescriptions of this nature, so data between March 2020 and August 2020 is currently unavailable.</p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 82095 question first answered 14/09/2020 19:12:55 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan

1189310

registered interest
date	22/04/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many prescriptions for cannabis-based products for medicinal use have been issued on the NHS since the rescheduling of those products.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	39000
answer	answer is ministerial correction date of answer 04/05/2020 answer text <p>There have been 3,546 items for licensed and unlicensed cannabis-based medicines prescribed on a National Health Service prescription, dispensed in the community in England and submitted to the NHS Business Services Authority for reimbursement for the period November 2018 to February 2020 (latest data available).</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 04/05/2020 13:01:12 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan

1189313

registered interest
date	22/04/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, with reference to the guidance entitled, The supply, manufacture, importation and distribution of unlicensed cannabis-based products for medicinal use in humans specials, published by the Medicines and Healthcare Products Regulatory Agency in March 2020, what discussions officials in his Department have had with officials in the Home Office on ensuring that import licences for cannabis-based products for medicinal use are granted without delay; and if he will make a statement.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	39003
answer	answer is ministerial correction date of answer 04/05/2020 answer text <p>The Department continues to work closely with the Home Office and the Medicines and Healthcare products Regulatory Agency (MHRA) to maintain the supply of unlicensed cannabis-based products for medicinal use (CBPMs) to ensure that patients with prescriptions from specialist doctors can access their medicine. The Home Office and the MHRA treat all import requests for CBPMs as emergency supplies, and on receipt of the correct documentation, applicants receive decisions within a few working days.</p><p>The Government made changes to import policy in March 2020 to enable pharmaceutical wholesalers to apply to import CBPMs in anticipation of prescriptions, instead of only applying to import the quantity specified on a prescription. We are continuing to work with industry to ensure supply remains uninterrupted during the COVID-19 outbreak.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 04/05/2020 13:04:04 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan

1173615

registered interest
date	27/01/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions officials of his Department has had with officials of the Home Office to ensure there are no undue delays in granting import licences for cannabis-based products for medicinal use; and if he will make a statement.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	8359
answer	answer is ministerial correction date of answer 04/02/2020 answer text <p>We are aware that some wholesalers and pharmacies have reported challenges in importing a range of unlicensed cannabis-based products for medicinal use. It is clear that for some products, long lead times and delays in receiving export licences from the authorities in the country of manufacture, have led to delays in the supply against prescriptions and pose a potential risk to patients receiving their medicines on time.</p><p>The Department, the Medicines and Healthcare products Regulatory Agency (MHRA), the Home Office, NHS England and NHS Improvement are in the process of agreeing what action can be taken to help alleviate these delays, including exploring mechanisms to allow licensed wholesalers to hold a small reserve stock linked to an evidenced demand by specialist prescribers; and ensuring that the United Kingdom meets its obligations under the Single Convention on Narcotic Drugs. Any changes will be reflected in the guidance published by the MHRA.</p><p>In the meantime, the Home Office and the MHRA are treating all import requests for cannabis-based products for medicinal use as emergency supplies and on receipt of the correct documentation, applicants can expect a decision within a few working days.</p><p>No meetings have taken place with representatives of patient groups concerning the reported delays to imports of cannabis-base products for medicinal use. Officials did meet with patient groups in the development of this policy when the previous Government rescheduled cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001.</p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 8360 8361 question first answered 04/02/2020 17:26:56 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan

1173616

registered interest
date	27/01/2020
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what meetings (a) he, (b) Special Advisers to ministers of his Department, and (c) officials of his Department have attended with representatives of patient groups on the import of cannabis-based products for medicinal use since 1 January 2018.
tabling member constituency	Inverclyde
tabling member printed	Ronnie Cowan
uin	8360
answer	answer is ministerial correction date of answer 04/02/2020 answer text <p>We are aware that some wholesalers and pharmacies have reported challenges in importing a range of unlicensed cannabis-based products for medicinal use. It is clear that for some products, long lead times and delays in receiving export licences from the authorities in the country of manufacture, have led to delays in the supply against prescriptions and pose a potential risk to patients receiving their medicines on time.</p><p>The Department, the Medicines and Healthcare products Regulatory Agency (MHRA), the Home Office, NHS England and NHS Improvement are in the process of agreeing what action can be taken to help alleviate these delays, including exploring mechanisms to allow licensed wholesalers to hold a small reserve stock linked to an evidenced demand by specialist prescribers; and ensuring that the United Kingdom meets its obligations under the Single Convention on Narcotic Drugs. Any changes will be reflected in the guidance published by the MHRA.</p><p>In the meantime, the Home Office and the MHRA are treating all import requests for cannabis-based products for medicinal use as emergency supplies and on receipt of the correct documentation, applicants can expect a decision within a few working days.</p><p>No meetings have taken place with representatives of patient groups concerning the reported delays to imports of cannabis-base products for medicinal use. Officials did meet with patient groups in the development of this policy when the previous Government rescheduled cannabis-based products for medicinal use under the Misuse of Drugs Regulations 2001.</p><p> </p><p> </p> answering member constituency Bury St Edmunds answering member printed Jo Churchill grouped question UIN 8359 8361 question first answered 04/02/2020 17:26:56 answering member 4380 label Biography information for Jo Churchill
tabling member	4465 label Biography information for Ronnie Cowan